Bristol-Myers Squibb (NYSE:BMY) Position Lessened by Alan B Lancz & Associates Inc.

Alan B Lancz & Associates Inc. reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,750 shares of the biopharmaceutical company’s stock after selling 600 shares during the quarter. Alan B Lancz & Associates Inc.’s holdings in Bristol-Myers Squibb were worth $382,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in BMY. Insight Inv LLC increased its position in shares of Bristol-Myers Squibb by 39.0% during the 4th quarter. Insight Inv LLC now owns 30,859 shares of the biopharmaceutical company’s stock valued at $1,745,000 after purchasing an additional 8,663 shares during the period. Advocate Group LLC boosted its stake in Bristol-Myers Squibb by 5.8% during the fourth quarter. Advocate Group LLC now owns 145,177 shares of the biopharmaceutical company’s stock valued at $8,211,000 after buying an additional 7,936 shares in the last quarter. Toth Financial Advisory Corp grew its holdings in Bristol-Myers Squibb by 28.2% during the fourth quarter. Toth Financial Advisory Corp now owns 73,018 shares of the biopharmaceutical company’s stock worth $4,130,000 after acquiring an additional 16,041 shares during the period. Geneos Wealth Management Inc. raised its position in Bristol-Myers Squibb by 3.9% in the fourth quarter. Geneos Wealth Management Inc. now owns 95,955 shares of the biopharmaceutical company’s stock worth $5,427,000 after acquiring an additional 3,560 shares in the last quarter. Finally, Accel Wealth Management lifted its holdings in Bristol-Myers Squibb by 6.2% in the 4th quarter. Accel Wealth Management now owns 4,674 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 271 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Trading Up 0.9 %

Shares of NYSE BMY opened at $59.68 on Friday. The business has a 50 day simple moving average of $57.47 and a 200 day simple moving average of $52.54. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The stock has a market cap of $121.05 billion, a price-to-earnings ratio of -16.63, a PEG ratio of 2.02 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.49 by $0.31. The company had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.00 earnings per share. On average, research analysts predict that Bristol-Myers Squibb will post 0.92 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a $0.62 dividend. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.16%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is currently -69.08%.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,830 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was purchased at an average price of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BMY shares. Barclays raised their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. Morgan Stanley boosted their target price on Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Bank of America reiterated a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Finally, UBS Group upped their price objective on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $56.27.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.